文献速递关节外科

地塞米松与全膝及全髋关节置换术后静脉血栓栓塞并发症的剂量依赖性降低相关

Dexamethasone Is Associated With a Dose-Dependent Reduction in Venous Thromboembolic Complications Following Total Knee and Hip Arthroplasty.
PubMed 文献 · J Arthroplasty · 2026-07-16

该研究基于美国全国医疗数据库,纳入2016至2023年行初次全膝或全髋关节置换术的成年患者,比较围手术期不同剂量地塞米松与90天静脉血栓栓塞(VTE)并发症的关联。结果显示,全膝关节置换术患者各剂量组VTE调整比值比均显著低于未用药组,全髋关节置换术患者仅中、高剂量组显著降低,提示较高剂量地塞米松与较低VTE并发症发生率相关。

要点

  • 全膝关节置换术患者低、中、高剂量地塞米松组VTE风险均显著低于未用药组。
  • 全髋关节置换术患者仅中剂量和高剂量地塞米松组VTE风险显著降低。
  • 关节置换外科医生可考虑将较高剂量地塞米松作为标准VTE药物预防的围手术期辅助措施。

核心结论

  • 接受较高剂量地塞米松的患者VTE并发症发生率较低。
  • 关节置换外科医生可考虑将较高剂量地塞米松作为标准VTE药物预防方案的围手术期辅助措施。

研究设计与样本

  • 使用覆盖美国约25%住院手术的全国医疗数据库,识别2016至2023年行初次全膝和全髋关节置换术的成年患者。
  • 将手术当日接受地塞米松的患者分为未用药、低剂量(小于8 mg)、中剂量(8至12 mg)和高剂量(大于16 mg)队列,采用混合效应逻辑回归比较结局。
  • 主要结局为90天VTE并发症的调整比值比。

主要发现

  • 全膝关节置换术患者(n=946,019)中,未用药393,971例(41.7%),低剂量161,287例(17.1%),中剂量310,595例(32.8%),高剂量80,166例(8.5%)。
  • 全髋关节置换术患者(n=537,684)中,未用药239,671例(44.6%),低剂量80,166例(14.9%),中剂量151,875例(28.3%),高剂量66,482例(12.4%)。
  • 全膝关节置换术队列中,与未用药组相比,低剂量组aOR 0.93(95%CI 0.87至0.99,P=0.020),中剂量组aOR 0.84(95%CI 0.80至0.89,P<0.001),高剂量组aOR 0.79(95%CI 0.72至0.88,P<0.001)。
  • 全髋关节置换术队列中,仅中剂量组aOR 0.85(95%CI 0.77至0.94,P=0.001)和高剂量组aOR 0.78(95%CI 0.64至0.94,P=0.009)的VTE调整比值比显著低于未用药组。

临床怎么用

  • 在全膝和全髋关节置换术围手术期,可考虑使用较高剂量地塞米松作为标准VTE药物预防的辅助手段,以降低VTE并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) following total knee (TKA) and hip (THA) may be mediated by postoperative inflammatory dysregulation. Emerging literature has suggested that perioperative dexamethasone may reduce the risk of VTE by mitigating inflammation-driven thrombogenesis. The present study sought to compare postoperative VTE complications across patients receiving varying perioperative dexamethasone doses. METHODS: Using a national healthcare database that captures approximately 25% of inpatient procedures in the United States, we identified adult patients undergoing primary TKA and THA between 2016 and 2023. Patients who received dexamethasone on the day of surgery were identified and stratified into either a no dexamethasone, low-dose (less than eight milligrams [mg]), medium-dose (eight to 12 mg), or high-dose (greater than 16 mg) cohort. Outcomes were compared between the cohorts utilizing mixed-effects logistic regression. The primary outcome was the 90-day adjusted odds of VTE complications. RESULTS: Among TKA patients (n = 946,019), 393,971 (41.7%) did not receive dexamethasone, 161,287 (17.1%) received low-dose, 310,595 (32.8%) received medium-dose, and 80,166 (8.5%) received high-dose. Among THA patients (n = 537,684), 239,671 (44.6%) did not receive dexamethasone, 80,166 (14.9%) received low-dose, 151,875 (28.3%) received medium-dose, and 66,482 (12.4%) received high-dose. Within the TKA cohort, all dosing groups had significantly lower adjusted odds of VTE compared to the unexposed patients (low dose - adjusted odds ratio [aOR]: 0.93, 95% confidence interval [CI]: 0.87 to 0.99, P = 0.020; medium dose - aOR: 0.84, 95% CI: 0.80 to 0.89, P < 0.001; high dose - aOR: 0.79, 95% CI: 0.72 to 0.88, P < 0.001) when compared to those who did not receive dexamethasone. For THA patients, the adjusted odds of VTE were significantly lower in just the medium (aOR: 0.85, 95% CI: 0.77 to 0.94, P = 0.001) and high dose (aOR: 0.78, 95% CI: 0.64 to 0.94, P = 0.009) groups. CONCLUSIONS: Patients who received higher doses of dexamethasone experienced lower rates of VTE complications. Arthroplasty surgeons should consider higher doses of dexamethasone as a perioperative adjunct to standard VTE chemoprophylaxis regimens.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Telang SS, Wier J, Jones IA, et al. Dexamethasone Is Associated With a Dose-Dependent Reduction in Venous Thromboembolic Complications Following Total Knee and Hip Arthroplasty. J Arthroplasty. 2026. PMID: 42462881. doi:10.1016/j.arth.2026.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。